Medasense Biometrics Ltd. “Medasense” is a medical device company that has developed an innovative, platform technology that can objectively assess and monitor changes in a patient’s pain level by processing multiple physiological parameters affected by pain and by analgesic administration. Until now, clinicians have had to rely on a patients’ subjective assessment or their own judgement where patients are unable to communicate their pain (under sedation, babies/children, mentally ill, etc.). Better assessment of pain can contribute to improved clinical outcomes and a reduction in costs associated with non-optimal pain management. Medasense's flagship product, the PMD-200™, is an objective pain monitoring system for operating rooms and critical care, where patients under general anesthesia are unable to communicate their pain. The system consists of a non-invasive finger probe that records multiple pain-related physiological signals, and the PMD-200™ monitor, which uses a composite algorithm to determine an individual’s real-time, pain level index - NoL™. Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced statistical modeling to convert complicated data into a patient's “Signature of Pain”. The NoL Index enables clinicians to optimize and personalize pain management, helping improve patient outcomes at hospitals, clinics, and in the home.

Medasense Biometrics Ltd. “Medasense” is a medical device company that has developed an innovative, platform technology that can objectively assess and monitor changes in a patient’s pain level by processing multiple physiological parameters affected by pain and by analgesic administration. Until now, clinicians have had to rely on a patients’ subjective assessment or their own judgement where patients are unable to communicate their pain (under sedation, babies/children, mentally ill, etc.). Better assessment of pain can contribute to improved clinical outcomes and a reduction in costs associated with non-optimal pain management. Medasense's flagship product, the PMD-200™, is an objective pain monitoring system for operating rooms and critical care, where patients under general anesthesia are unable to communicate their pain. The system consists of a non-invasive finger probe that records multiple pain-related physiological signals, and the PMD-200™ monitor, which uses a composite algorithm to determine an individual’s real-time, pain level index - NoL™. Considering the complex nature of pain, Medasense technology uses a unique multi-parametric approach and advanced statistical modeling to convert complicated data into a patient's “Signature of Pain”. The NoL Index enables clinicians to optimize and personalize pain management, helping improve patient outcomes at hospitals, clinics, and in the home.

• Clinician controlled EHR pathways. No need after initial integration for IS involvement with routine clinical changes to pathway logic, orders, etc.
• Integrated content marketplace for sharing and copying other organizations (even on different EHRs) clinical pathways
• Advanced diagramming tools specific to clinical decision trees unavailable in EHRs.